| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |